Arvinas, Inc. (ARVN): Price and Financial Metrics

Arvinas, Inc. (ARVN)

Today's Latest Price: $34.22 USD

0.29 (0.85%)

Updated Jul 9 6:55pm

Add ARVN to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 213 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

ARVN Stock Summary

  • With a one year PEG ratio of 0.27, Arvinas Inc is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than just 5.22% of US stocks.
  • ARVN's went public 1.78 years ago, making it older than merely 3.3% of listed US stocks we're tracking.
  • With a price/sales ratio of 29.39, Arvinas Inc has a higher such ratio than 94.34% of stocks in our set.
  • Stocks that are quantitatively similar to ARVN, based on their financial statements, market capitalization, and price volatility, are CLLS, BLUE, ZYME, CUE, and ASMB.
  • Visit ARVN's SEC page to see the company's official filings. To visit the company's web site, go to
ARVN Daily Price Range
ARVN 52-Week Price Range

ARVN Stock Price Chart Technical Analysis Charts

ARVN Price/Volume Stats

Current price $34.22 52-week high $61.57
Prev. close $33.93 52-week low $15.19
Day low $33.17 Volume 365,100
Day high $34.49 Avg. volume 486,519
50-day MA $39.62 Dividend yield N/A
200-day MA $38.84 Market Cap 1.34B

Arvinas, Inc. (ARVN) Company Bio

Arvinas Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead products include ARV-110, proteolysis targeting chimeras (PROTAC) targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer; and ARV-471, a PROTAC targeting the estrogen receptor protein for the treatment of women with metastatic ER+ breast cancer. The company is also developing other PROTACs for degrading AR and other clinically relevant AR point mutations; and various other products for the treatment of neurodegenerative diseases, including tauopathies. Arvinas Holding Company, LLC was founded in 2015 and is based in New Haven, Connecticut.

ARVN Latest News Stream

Event/TimeNews Detail
Loading, please wait...

ARVN Latest Social Stream

Loading social stream, please wait...

View Full ARVN Social Stream

Latest ARVN News From Around the Web

Below are the latest news stories about Arvinas Inc that investors may wish to consider to help them evaluate ARVN as an investment opportunity.

Nurix Therapeutics Files For U.S. IPO

Quick Take Nurix Therapeutics (NRIX) has filed to raise $100 million in an IPO of its common stock, according to an S-1 registration statement. The company is developing small molecule-based treatments for blood cancers and immune system conditions. NRIX is a promising biopharma with substantial major pharma partnerships, but has...

Donovan Jones on Seeking Alpha | July 8, 2020

Arvinas Appoints Wendy Dixon, Ph.D., to its Board of Directors

NEW HAVEN, Conn., June 29, 2020 -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation,.

Yahoo | June 29, 2020

Arvinas to Present Virtually at the BMO 2020 Prescriptions for Success Healthcare Conference

NEW HAVEN, Conn., June 17, 2020 -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation,.

Yahoo | June 17, 2020

Here is What Hedge Funds Think About Arvinas, Inc. (ARVN)

In this article you are going to find out whether hedge funds think Arvinas, Inc. (NASDAQ:ARVN) is a good investment right now. We like to check what the smart money thinks first before doing extensive research on a given stock. Although there have been several high profile failed hedge fund picks, the consensus picks among […]

Yahoo | June 15, 2020

Arvinas (ARVN) Investor Presentation - Slideshow

The following slide deck was published by Arvinas, Inc. in conjunction with this event....

SA Transcripts | June 12, 2020

Read More 'ARVN' Stories Here

ARVN Price Returns

1-mo 2.36%
3-mo N/A
6-mo -26.41%
1-year 36.39%
3-year N/A
5-year N/A
YTD -16.72%
2019 219.77%
2018 N/A
2017 N/A
2016 N/A
2015 N/A

Continue Researching ARVN

Here are a few links from around the web to help you further your research on Arvinas Inc's stock as an investment opportunity:

Arvinas Inc (ARVN) Stock Price | Nasdaq
Arvinas Inc (ARVN) Stock Quote, History and News - Yahoo Finance
Arvinas Inc (ARVN) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8381 seconds.